COVID-19 – Indonesia issues emergency use for five booster vaccines
National

COVID-19 – Indonesia issues emergency use for five booster vaccines

Jakarta (Indonesia Window) – Indonesia’s National Agency of Drug and Food Control (BPOM) has issued an Emergency Use Authorization (EUA) for five COVID-19 vacci...

Indonesia Window

11 January 2022

COVID-19 – Indonesia approves China’s Zifivax vaccine for booster
National

COVID-19 – Indonesia approves China’s Zifivax vaccine for booster

Jakarta (Indonesia Window) – Zifivax vaccine has received an Emergency Use Authorization (EUA) as a booster dose from Indonesia’s National Agency of Drug and Fo...

Indonesia Window

11 January 2022

COVID-19 – Indonesia issues emergency use authorization for Molnupiravir antivirus
National

COVID-19 – Indonesia issues emergency use authorization for Molnupiravir antivirus

Jakarta (Indonesia Window) – Indonesia’s National Agency of Drug and Food Control (BPOM) has issued an emergency use authorization (EUA) for the COVID-19 antivi...

Indonesia Window

15 January 2022

COVID-19 – Indonesia issues EUA for Paxlovid as medicine
National

COVID-19 – Indonesia issues EUA for Paxlovid as medicine

"The recommended dose is 300 mg Nirmatrelvir (two 150 mg tablets) with 100 mg Ritonavir (one 100 mg tablet) taken together twice a day for five days." Jakarta (...

Indonesia Window

18 July 2022

COVID-19 – Indonesia approves Comirnaty for booster on children 16-18 yo
National

COVID-19 – Indonesia approves Comirnaty for booster on children 16-18 yo

A clinical study on children aged 16 years old and above (test subject C4591031 Sub A) showed an efficacy of 95.6 percent in preventing the occurrence of COVID-...

Indonesia Window

03 August 2022

Indovac and AWcorna vaccines
National

COVID-19 – Indonesia issues EUA for Indovac vaccine, AWcorna vaccine

Indovac and AWcorna vaccines have received Emergency Use Authorization (EUA) for the prevention of COVID-19 caused by SARS CoV-2 for individuals aged 18 years a...

Indonesia Window

30 September 2022

Logo
Tentang KamiPrivasiHubungi Kami